Piper Sandler Initiates Coverage On Generate Biomedicines with Overweight Rating, Announces Price Target of $24

Benzinga Newsdesk www.benzinga.com Neutral 63.2%

Neg 0% Neu 63.2% Pos 0%

Piper Sandler analyst Edward Tenthoff initiates coverage on Generate Biomedicines (NASDAQ:GENB) with a Overweight rating and announces Price Target of $24.